Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases May 8, 2026 8:30 AM EDTCompany ...
CLYM116 modeling and initial Phase 1 safety data to be presented at ERA 2026 with initial Phase 1 PK/PD data expected mid-2026 Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; ...
Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM ...
InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ...
Record-setting scale: Researchers simulated protein-ligand complexes up to 12,635 atoms, the largest hybrid quantum-classical chemistry calculation for a biologically relevant system. Hybrid workflow: ...